Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck & Co., Inc. : Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2012 | 07:50pm CET

A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx.

In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation.

Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes.

"The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement.

In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations.

Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year.

-By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21 MERCK : StayWell and VUCA Health Collaborate to Expand Availability of Medicatio..
02/21 BRISTOL-MYERS SQUIBB CO (NYSE : BMY), Merck & Co., Inc. (NYSE:MRK), And Other Ph..
02/20 MERCK : StayWell and VUCA Health Collaborate to Expand Availability of Medicatio..
02/16 MERCK : Studies from Merck & Company Provide New Data on Laboratory Animal Resea..
02/16 MERCK : Studies from Merck & Company Update Current Data on Science (Development..
02/16 MERCK : Studies from Merck & Company Update Current Data on Tuberculosis (Thiazo..
02/16 MERCK : New Findings from Merck & Company Describe Advances in Analytical Scienc..
02/16 MERCK : Data on Science Reported by Researchers at Merck & Company (Structural c..
02/16 MERCK : Investigators at Merck & Company Describe Findings in Alimentary Pharmac..
More news
Sector news : Pharmaceuticals - NEC
08:48aDJBRISTOL MYERS SQUIBB : New Pressure on Drug Giant -- WSJ
08:48aDJWHAT'S NEWS : Business & Finance -- WSJ
08:02aDJBAYER : Fourth-Quarter Net Profit Falls 26%
02:05aDJBRISTOL MYERS SQUIBB : Carl Icahn Takes Stake in Bristol-Myers Squibb -- 2nd Upd..
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/21 HEPATITIS B MARKET : Emerging Players Could Make The Difference
02/21 Merck Provides Keytruda For Bionomics Phase 1 Trial On Combination With BNC10..
02/21 ALLERGAN REPORTS Q4 : Multiple Analyses
02/21 BIOTECH FORUM DAILY DIGEST : Biotech Continues To Gain Momentum. Alzheimer's Res..
02/17 INCYTE : Many Strengths, Small EPS, So What's It Worth?
Advertisement
Financials ($)
Sales 2017 39 728 M
EBIT 2017 13 523 M
Net income 2017 8 459 M
Debt 2017 3 738 M
Yield 2017 2,87%
P/E ratio 2017 19,13
P/E ratio 2018 15,96
EV / Sales 2017 4,64x
EV / Sales 2018 4,50x
Capitalization 180 537 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 68,5 $
Spread / Average Target 4,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.11.23%180 537
JOHNSON & JOHNSON3.86%325 539
ROCHE HOLDING LTD.4.90%212 000
PFIZER INC.3.51%204 018
NOVARTIS AG3.51%202 892
SANOFI4.72%109 519
More Results